
New York (AP) - A third leading candidate COVID-19 vaccine has entered a final stage of human testing in the United States.
AstraZeneca announced Monday its potential COVID-19 vaccine has entered final trials in the U.S. to test the effectiveness and safety of the product.
The Cambridge, England-based company said the trial will involve up to 30,000 adults from various racial, ethnic, and geographic groups.
The potential vaccine was invented by the University of Oxford and an associated company, Vaccitech.
Meanwhile, a U.S. advisory panel is suggesting a way to ration the first limited doses once a vaccine does prove safe and effective.


School superintendent outlines when more students may be able to return to classrooms
Tlingit artist chosen to create stamp for U.S. Post Service
Barge rate increase expected to raise Alaska consumer prices
Many Alaska adults have risk factors for severe COVID-19
Ketchikan adds three new cases of COVID-19
State reports 523 new cases of COVID-19
8 rescued from frigid waters
39 new Officers graduate from Public Safety Academy
Winter Route change for Capital Transit on Saturday
Barrett sentenced for 2016 killing of 16-year-old boy
State threatens eminent domain over Native allotment
Salvation Army Thanksgiving event to be held downtown